1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Chempartner Pharmatech Co., Ltd.
  6. Summary
    300149   CNE100000Y27

CHEMPARTNER PHARMATECH CO., LTD.

(300149)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-08-04
10.89 CNY   +2.74%
06/09Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd..
CI
05/08Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding
CI
05/05Jiangmen Xinhui Hefeng Trading Co., Ltd. completed the acquisition of Quantum Hi-Tech Health Technology Co., Ltd from Chempartner Pharmatech Co., Ltd..
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
10.94 10.43 10.27 10.6 10.89 Last
2251400 5048045 2679253 3713006 3585800 Volume
+0.09% -4.66% -1.53% +3.21% +2.74% Change
Estimated financial data (e)
Sales 2020 1 482 M - -
Net income 2020 155 M - -
Net Debt 2020 906 M - -
P/E ratio 2020 47,6x
Yield 2020 0,48%
Sales 2021 1 691 M - -
Net income 2021 -402 M - -
Net Debt 2021 1 568 M - -
P/E ratio 2021 -17,0x
Yield 2021 -
Capitalization 5 427 M 803 M -
EV / Sales 2020 5,58x
EV / Sales 2021 5,00x
Nbr of Employees 2 636
Free-Float 23,1%
More Financials
Company
ChemPartner PharmaTech Co Ltd, formerly Quantum Hi-tech China Biological Co Ltd, is a China-based company principally engaged in the research, development, production, and sales of fructooligosaccharides and other prebiotics. The Company's main products include fructooligosaccharides and galactooligosaccharides. The Company owns brands names of FOS and GOS. The Company's products are mainly used in nutrition and... 
Sector
Food Processing
Calendar
08/30Earnings Release
More about the company
All news about CHEMPARTNER PHARMATECH CO., LTD.
06/09Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech Biological..
CI
05/08Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million i..
CI
05/05Jiangmen Xinhui Hefeng Trading Co., Ltd. completed the acquisition of Quantum Hi-Tech H..
CI
04/29Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended M..
CI
03/31Tate & Lyle To Pay $237 Million For Chinese Prebiotic Dietary Fiber Business
MT
03/31Tate & Lyle Investments Limited agreed to acquire Quantum Hi-Tech Biological Co., Ltd. ..
CI
03/09Porton Pharma Solutions Ltd. agreed to acquire Kaihui Pharmaceutical Co., Ltd. from Che..
CI
01/21Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on J..
CI
01/21Chempartner Pharmatech Co., Ltd.'s Equity Buyback announced on January 22, 2021, has ex..
CI
01/05Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on J..
CI
2021Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended Sep..
CI
2021Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on J..
CI
2021Chempartner Pharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June ..
CI
2021Tranche Update on Chempartner Pharmatech Co., Ltd.'s Equity Buyback Plan announced on J..
CI
2021Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 J..
CI
More news
News in other languages on CHEMPARTNER PHARMATECH CO., LTD.
06/09TATE & LYLE INVESTMENTS LIMITED A FI : 300149).
05/05JIANGMEN XINHUI HEFENG TRADING CO., : 300149).
04/29Chempartner Pharmatech Co., Ltd. annonce ses résultats pour le premier trimestre se ter..
03/31Tate & Lyle va payer 237 millions de dollars pour son activité chinoise de fibres alime..
2021Chempartner Pharmatech Co., Ltd. annonce le versement d'un dividende final en espèces p..
More news
Chart CHEMPARTNER PHARMATECH CO., LTD.
Duration : Period :
Chempartner Pharmatech Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHEMPARTNER PHARMATECH CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Managers and Directors
Feng Mao Hua Chief Executive Officer & Director
Dan Ying Xia Chief Financial Officer
Da Chao Zhang Chairman-Supervisory Board
Swee Lian Woo Chairman
Xian Zhong Wang Independent Director
Sector and Competitors